Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dacogen

- PMLiVE

Unions blast ‘negative consequences’ for Sweden of a Pfizer-AZ deal

Say proposed takeover posed an imminent risk to country's life science sector

- PMLiVE

Abbott strikes $3.3bn Latin America generics deal

Boosts portfolio in region with acquisition of CFR Pharmaceuticals

- PMLiVE

AstraZeneca rejects ‘final offer’ from Pfizer

And US pharma company rules out hostile takeover

Bristol-Myers Squibb (BMS) building

BMS’ nivolumab gets breakthrough status

But shares fall on concerns over new trial data

- PMLiVE

Macmillan campaign for legacy donations

Cancer charity aims to raise awareness of the importance of gifts in wills

- PMLiVE

MPs grill Read over Pfizer’s commitments to UK

CEO faces combative parliamentary hearing over AstraZeneca bid

- PMLiVE

Battle lines drawn as Allergan rejects Valeant offer

Turns down $47bn takeover bid saying it undervalues the company

- PMLiVE

St Ives buys Hive

Says healthcare consultancy complements the company’s existing offering

- PMLiVE

Bayer buys Merck consumer health unit

Continues trend for major pharma deals

- PMLiVE

Pfizer faces opposition to AZ takeover as Q1 figures disappoint

Labour leader Ed Miliband calls for public inquiry into deal

- PMLiVE

UPDATE: AZ rejects improved Pfizer bid

Continues to assert independence as Pfizer appeals to Prime Minister David Cameron

- PMLiVE

Otsuka wins approval for TB drug Deltyba

Second drug approved by EC in 2014 for multidrug resistant tuberculosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links